With immunotherapy emerging as one of the most important treatment options in oncology, GE HealthCare has announced the first patient scanned in a Phase I clinical trial of a first-of-its kind fluorine-18 PET radiopharmaceutical specific for CD8, which is expressed on CD8+ T cells – a subpopulation of white blood cells which fight cancer.
